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Abstract
Ulifloxacin is the active form of the prodrug prulifloxacin and shows a highly potent antipseu-
domonal activity. In this study, we examined the combined effect of fosfomycin and ulifloxacin
against Pseudomonas aeruginosa (P. aeruginosa) growing in a biofilm using a modified Rob-
bins device with artificial urine, and compared it to that of the combination of fosfomycin and
ciprofloxacin or levofloxacin. An ATP bioluminescence assay was used to evaluate the antibac-
terial activity of the agents against sessile cells in a mature biofilm developed on a silicon disk.
The total bioactivity of P. aeruginosa growing in a biofilm that had not been fully eradicated by
fosfomycin or any of the fluoroquinolones alone at 10 times the MIC decreased after combina-
tion treatment with fosfomycin and fluoroquinolones. Morphological changes occurred in a time-
dependent fashion; namely, swollen and/or rounding cells emerged within a couple of hours after
combination treatment, marking the initial stage in the process leading to the destruction of the
biofilms. We could not find any difference among the 3 fluoroquinolones with regard to their syn-
ergistic effects when administered with fosfomycin. The combination treatment of fosfomycin and
fluoroquinolones with highly potent antipseudomonal activities was effective in eradicating ses-
sile cells of P. aeruginosa in the biofilm and promises to be beneficial against biofilm-associated
infectious diseases.
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Uliﬂoxacin is the active form of the prodrug pruliﬂoxacin and shows a highly potent anti-
pseudomonal activity. In this study, we examined the combined eﬀect of fosfomycin and uliﬂoxacin against ( )growing in a bioﬁlm using a modiﬁed Robbins device with artiﬁcial urine, and compared it to that of the combination of fosfomycin and ciproﬂoxacin or levoﬂoxacin. An ATP bioluminescence assay was used to evaluate the antibacterial activity of the agents against sessile cells in a mature bioﬁlm developed on a silicon disk. The total bioactivity of  growing in a bioﬁlm that had not been fully eradicated by fosfomycin or any of the ﬂuoroquinolones alone at 10 times the MIC decreased after combination treatment with fosfomycin and ﬂuoroquinolones. Morphological changes occurred in a time-dependent fashion;
namely, swollen and/or rounding cells emerged within a couple of hours after combination treat-
ment, marking the initial stage in the process leading to the destruction of the bioﬁlms. We could not ﬁnd any diﬀerence among the 3 ﬂuoroquinolones with regard to their synergistic eﬀects when admi
 
e type of P. aeruginosa in
 
n. The combination treatment of fosfomycin and ﬂuoroquinolones with highly potent antipseudomonal activities was eﬀective in eradicating sessile cells of in the bioﬁlm and promises to be beneﬁcial against bioﬁlm-associated infectious diseases.
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B acterial bioﬁlms play an important role in the development and persistence of various chronic intractable infectious diseases, including catheter-
associated urinary tract infections (UTI)［1-4］. The isolation frequencies of Pseudomonas aeruginosa (P.
aeruginosa), a major pathogen in bioﬁlm-associated infec-
tion, are also elevated in cases of complicated UTI［5］.
The sessil
 
ence of many chronic infe bioﬁlms is protected
 
by an extracellular polymeric substance(glycocalyx)from various host defense mechanisms and is susceptible to antibiotics at 100 to 1000 times lower levels than equiva-
lent populations of planktonic bacteria［6-8］. The bioﬁlm infection itself is an indolent infection, although the stability of bioﬁlms is a major factor in the persist
 
al activity against non-
ctions.
Fluoroquinolones not only exert antimicrobial activity against a broad spectrum of organisms isolated from the urinary tract, but they also exert bactericid
 
killing eﬀect on the sess 
growing bacteria［8, 9］. In addition, ﬂuoro-
quinolones show a special  e ilec ll s
 
P  as aeruginosa seudomon
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of P. aeruginosa growing in mature bioﬁlms because of their penetrability through exopolysaccharides［8, 10］.
However, the number of favorable cases is much smaller than might be expected. Fosfomycin (FOM:1R-2S-
epoxypropylphosphonic acid)is a widely prescribed anti-
biotic with a unique chemical structure eﬀective against a broad spectrum of microbials［11］. FOM in combination with oﬂoxacin(OFLX)has been reported to exert clear synergistic eﬀects against sessile cells of P. aeruginosa growing in bioﬁlms, but combinations of FOM with other ﬂuoroquinolones have not yet been studied［12, 13］.
Uliﬂoxacin(UFX)is the active form of the prodrug pruliﬂoxacin, a new ﬂuoroquinolone antibacterial agent with a highly potent antipseudomonal activity［14］. UFX and ciproﬂoxacin (CPFX) have exhibited far stronger eﬀects than levoﬂoxacin (LVFX) in inhibiting DNA gyrase, the primary target of ﬂuoroquinolones in P.
aeruginosa［15］. Moreover, UFX is known to be accumulated in P. aeruginosa at higher concentrations than CPFX, with LVFX accumulating at the lowest concentration among the 3 agents［16］. At present, it remains unclear whether the antipseudomonal activity of ﬂuoroquinolone against ﬂoating cells reﬂects the eﬀectiveness of the eradication of sessile cells of P.
aeruginosa in bioﬁlms with or without FOM.
In this study, we focused on the combination treat-
ment of FOM and UFX with respect to eradication of sessile cells of P. aeruginosa in bioﬁlms using a modiﬁed Robbins device with artiﬁcial urine. At the same time,we observed time-dependent morphological changes by scan-
ning electron microscopy(SEM)to assess the process leading to the destruction of the bioﬁlms.
Materials and Methods
 
P. aeruginosa OP14-210 isolated from a patient with a catheter-associated UTI was used throughout this study
［12, 13］. UFX is an active metabolite of PUFX and was provided by Nihon Shinyaku, Ltd.(Kyoto, Japan).
FOM was supplied by Meiji Seika Kaisha (Tokyo,
Japan). CPFX and LVFX were purchased from Sequoia Research Products Ltd.(Oxford, United Kingdom).
In the present study, the minimum inhibitory concen-
tration(MIC)of each agent against P. aeruginosa OP14
-210 was determined by the macrodilution tube broth method with a ﬁnal inoculation of 5×10?colony-forming units (CFU)/ml using artiﬁcial urine supplemented with 0.4 (w/v)nutrient broth(AUB)(EIKEN CHEMICAL
 
CO., LTD., Tokyo, Japan) or Mueller-Hinton broth
(MHB) (DIFCO, BECTON DICKINSON, Sparks,
MO, USA)［13］. The minimum bactericidal concentra-
tion(MBC)of each antibiotic using AUB was deemed to have been achieved when the number of CFUs per milliliter was＜99.9  compared with the initial inoculum size［17］. We studied the activities of FOM in combina-
tion with each ﬂuoroquinolone against ﬂoating cells of P.
aeruginosa OP14-210 by the checkerboard method to calculate a fractional inhibitory concentration(FIC)index using AUB. The results were interpreted as synergism,
addition, indiﬀerence, or antagonism when the FIC indices were ≦0.5, 0.5 to 0.75, 1 to 4, and ＞4,
respectively［18］.
The culture conditions for production of an adherent bioﬁlm were essentially identical to those reported previ-
ously by Kumon et al.［13］. Brieﬂy, AUB containing logarithmic-phase P. aeruginosa OP14-210 was pumped from a reservoir through a modiﬁed Robbins device by a peristaltic pump set to deliver 40 ml/h. After 16 h of contact with P. aeruginosa OP14-210 at time zero for the treatment period by antimicrobial agents, a thick bioﬁlm developed on 10-mm silicon disks(Create Medic,
Yokohama, Japan)in the device. At time zero, AUB containing P. aeruginosa was exchanged to AUB containing FOM, UFX, CPFX, or LVFX alone or a combination of FOM plus either UFX, CPFX, or LVFX at appropriate concentrations, and ﬂowed through the modiﬁed Robbins device at 40 ml/h during the treat-
ment period. Disks were removed from the device at 2,
4, 8, 24 and 48 h.
Instead of viable cell counts, an ATP bioluminescence assay was used as previously reported［19］. Brieﬂy,
silicon disks were removed, washed with distilled water,
boiled at 100°C for 8 min with 500μl of distilled water,
and subjected to ultrasonication, followed by centrifuga-
tion at 15,000 rpm for 10 min. Supernatants were kept at－80°C until use. For quantiﬁcation of ATP contents,
we used ATP Assay System LL-100-1(TOYO B-Net,
Co., LTD., Tokyo, Japan)with Fluoroskan Ascent FL L-5210520(Labsystems, Helsinki, Finland). All assays were performed with 2 disks, and the values shown are the means of duplicate experiments.
The cells on each disk were ﬁxed with 2.5  glutaral-
dehyde in phosphate-buﬀered saline, post-ﬁxed with 2 tannic acid and 1  OsO?, and dehydrated through an ethanol series. The specimens were then dried in a critical-point dryer (HCP-II:Hitachi, Tokyo, Japan),
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coated with platinum-palladium, and observed with a JSM-6300F scanning microscope (JEOL DATUM LTD, Tokyo, Japan).
Results
 
Table 1 summarizes the MIC and MBC of FOM,
UFX, CPFX and LVFX against ﬂoating cells of P.
aeruginosa OP14-210 in AUB or MHB, as well as the results of checkerboard studies of the FOM-UFX,
FOM-CPFX, and FOM-LVFX combinations. The eﬀect of the FOM-ﬂuoroquinolone combination against P.
aeruginosa ﬂoating cells was additive(with FIC indexes between 0.5 and 0.75).
None of the ﬂuoroquinolones alone at 10 times the MIC resulted in a detectable decrease in the total bioactivity of sessile P. aeruginosa OP14-210 in a
 
mature bioﬁlm, nor did FOM alone(Fig. 1A, B). In the case of UFX and LVFX, there was no eﬀect even at 100
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Fig.1  Kinetics of P. aeruginosa eradication in a mature bioﬁlm by
(A)FOM at either 1×, 3×, or 10× MIC, (B)either UFX, CPFX,
or LVFX at 10× MIC. The values are the means of duplicate experiments.
Fig.2  Kinetics of P. aeruginosa eradication in a mature bioﬁlm by either UFX, CPFX, or LVFX at 10× MIC plus FOM at 3×MIC. (A)
within 24 h, (B)within 48 h. The values are the means of duplicate experiments.
Table 1  Minimum inhibitory concentration (MIC), minimum bactericidal concentration(MBC), and fractional inhibitory concentra-
tion(FIC)index of fosfomycin(FOM), uliﬂoxacin(UFX), ciproﬂoxacin
(CPFX), and levoﬂoxacin(LVFX)against P. aeruginosa OP14-210 in Mueller-Hinton broth (MHB) or artiﬁcial urine supplemented with 0.4% nutrient broth(AUB).
Drug  
MIC(μg/ml)
MHB  AUB
 
MBC(μg/ml)
AUB
 
FIC index
(combined with FOM)
AUB
 
FOM  32  64  128 ―
UFX  0.25  2  4  0.75 CPFX  0.25  4  16  0.75 LVFX  1  8  16  0.56
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times the MIC against bioﬁlms (data not shown). How-
ever, the combination treatment of FOM and any of the 3 ﬂuoroquinolones resulted in a decrease of total bioactivity of sessile cells in bioﬁlms at the same concen-
trations at which the drugs had not been eﬀective alone
(Fig. 2A, B). There was no diﬀerence among the 3 ﬂuoroquinolones in regard to their synergy with FOM. In the case of combination treatment with UFX and FOM,
the ATP content of bioﬁlm cells decreased in an FOM dose-dependent fashion(Fig. 3).
Fig. 4 shows ultrastructural changes of sessile cells of P. aeruginosa in a mature bioﬁlm at 48 h after treatment with UFX and/or FOM. The presence of bloated cells was characteristic of treatment with FOM(Fig. 4B), and elongated and swollen cells were observed after treatment with UFX (Fig. 4 C). Swollen and/or bloated cells accompanied with destruction of the bioﬁlms were obser-
ved after combination treatment (Fig. 4D). These mor-
phological changes were observed within a couple of hours after the combination treatment (Fig. 5). Similar mor-
phological changes were observed when sessile cells in
 
bioﬁlms were treated with FOM plus CPFX or LVFX,
instead of UFX(Fig. 6).
Fig.3  Kinetics of P. aeruginosa eradication in a mature bioﬁlm by UFX at 10× MIC plus FOM at either 1×, 3×, or 10× MIC. The values are the means of duplicate experiments.
A  B
 
C  D
 
Fig. 4  Morphological changes of P. aeruginosa in a mature bioﬁlm at 48 h after treatment with UFX and/or FOM. SEM, original magniﬁcation, × 8,000;Bar＝1μm. A, control;B, FOM 3× MIC;C, UFX 10× MIC;D, UFX 10× MIC plus FOM 3× MIC.
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 Discussion
 
As the use of implant devices increases, the risk of bioﬁlm infection tends to increase［3］. The isolation frequencies of non-uropathogenic bacteria which would not normally cause infection, like P. aeruginosa, have increased. P. aeruginosa bioﬁlms are detected on the surface of indwelling catheters, calculi, scar tissue produced by endoscopic surgery or necrotic tissue as-
sociated with urothelial tumors in the case of complicated urinary tract infections［5］.
In a short period, P. aeruginosa is capable of invad-
ing and adhering to the urinary tract to form a bioﬁlm,
accompanied with changes of gene expression. In the initial cell attachment phase, for example, alginate
(exopolysaccharide) synthesis is up-regulated within a couple of minutes after adhesion to a solid surface［20］.
Recently, it was observed that the expression of speciﬁc
 
A  B
 
C  D
 
E  F
 
Fig.5  Morphological changes of P. aeruginosa in a mature bioﬁlm observed within 24 h after treatment with UFX 10×MIC plus FOM 3×
MIC. SEM, original magniﬁcation, × 10,000;Bar＝1μm. A, 0 h;B, 2 h;C, 4 h;D, 6 h;E, 8 h;F, 24 h.
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 genes associated with bioﬁlm formation was controlled by a quorum-sensing system, thereby emphasizing the signiﬁcance of cell-to-cell interactions［21, 22］.
Fluoroquinolones show a considerable eﬀect on P.
aeruginosa bioﬁlms;however, it is still limited and insuﬃcient, leading to failure of the clinical therapy as incomplete eradication means an easy return to the previ-
ous condition. We also failed to destroy the bioﬁlms completely even after 48 h of treatment with UFX or LVFX at 100 times the MIC. Furthermore, the anti-
microbial activities of some agents are sometimes reduced due to the biological characteristics of bioﬁlms. Namely,
cationic agents like aminoglycosides,which show a critical antimicrobial activity against ﬂoating bacteria, would be trapped by the anionic polysaccharide matrix, reducing the concentration of the free drug［23, 24］. In addition,
aminoglycosides are less eﬀective under the anaerobic condition within bioﬁlms, compared to their eﬃcacy under aerobic conditions［25］.
Antimicrobial agents are not yet suﬃciently eﬀective
 
against bioﬁlm infection, especially in the chronic indolent phase. As things now stand, the only eﬀective method of treatment is to correct the obstruction and directly remove the bioﬁlm. In this regard, Kumon et al. demonstrated the signiﬁcant eﬀects of a combination treatment by OFLX and FOM against bioﬁlms using a modiﬁed Robbins device in vitro［12, 13］. In pursuit of a more eﬃcient method to eradicate sessile cells of P. aeruginosa in bioﬁlms,we therefore evaluated the combination eﬀects of FOM and UFX, which possesses a highly potent antipseudomonal activity.
In this study, we demonstrated the equivalent syner-
gistic eﬀects of UFX, CPFX, or LVFX plus FOM against sessile cells in a bioﬁlm. Importantly, synergistic eﬀects were conﬁrmed at a concentration easily achievable in the urine of patients treated with clinical oral doses of these drugs. The urinary concentration of these agents just before the next administration was more than 10 times the MIC against P. aeruginosa OP14-210［26-
29］. In addition to the 3 ﬂuoroquinolones studied here,
A  B
 
C  D
 
Fig.6  Morphological changes of P. aeruginosa in a mature bioﬁlm at 48 h after treatment with either UFX, CPFX, or LVFX plus FOM.
SEM, original magniﬁcation,× 8,000;Bar＝1μm. A, control;B, UFX 10× MIC plus FOM 3× MIC;C, CPFX 10× MIC plus FOM 3×
MIC;D, LVFX 10× MIC plus FOM 3× MIC.
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reports have demonstrated that other ﬂuoroquinolones predominantly excreted via the kidney(e.g., ﬂeroxacin)
acted synergistically with FOM against ﬂoating cells of P.
aeruginosa［30］. At present, however, it is not clear whether these other combinations would exercise the same eﬀect against sessile cells of P. aeruginosa in a bioﬁlm.
The mechanism behind the synergistic eﬀect of FOM and ﬂuoroquinolones remains unknown. In preliminary experiments, we observed that treatment of UFX with the enantiomer of FOM with no bactericidal activity did not elicit any signiﬁcant decrease of the ATP contents of bacteria growing in a bioﬁlm(data not shown). Under the anaerobic conditions of cells embedded in a bioﬁlm, the levels of sn-glycerol 3-phoshate transport, the transport system that delivers FOM into bacterial cells, will increase［31］. Therefore, FOM is still transported into cells in the stationary phase and can be expected to provide a potential eﬀect against sessile cells with low growth rates. We also conﬁrmed that FOM did not react with the negatively charged bacterial glycocalyx, implying that FOM is able to penetrate deeply into the multilayers of the bioﬁlms［8］.
As a general role in Gram-negative organisms, hydro-
philic quinolones cross the outer membrane through porins while hydrophobic quinolones appear to enter via lipopolysaccharides(LPS)or cross the lipid bilayer［32］.
Increased susceptibility to hydrophobic quinolones has been described in LPS-defective mutants. On this basis,
we can postulate that the disruption and/or break of the outer membrane by FOM accelerates the quinolone uptake by passive diﬀusion［32］. In contrast, the hydrophilic ﬂuoroquinolones UFX and CPFX do not alter the antimicrobial activity against LPS-defective mutants［33］. As P. aeruginosa initially accumulates these hydrophilic ﬂuoroquinolones at higher concentra-
tions than it accumulates LVFX, it may be possible to accelerate the accumulation in the presence of FOM.
These observations suggested that the bactericidal activity of the combination of FOM and ﬂuroquinolones might be suﬃcient to completely eradicate the sessile cells in a bioﬁlm.
In the case of indolent infection with bioﬁlm diseases,
in general a sudden elevation of the pressure in the urinary tract caused by a mechanical obstruction introduces planktonic cells into the renal parenchyma and blood vessels, despite the presence of mucosal host defense systems［5, 34］. Under these severe life-threatening conditions, which are uroseptic, selective use of car-
bapenems as a potential empiric antibiotic is justiﬁed.
However, treatment with a carbapenem alone would fail to completely destroy the bioﬁlm, even if it could be rescued. Furthermore, insuﬃcient eradication of bioﬁlms would cause repeated life-threatening infections. Combi-
nation therapy using ﬂuoroquinolones and FOM after carbapenem treatment appears to be eﬀective in complete-
ly eradicating bioﬁlms and promises to be of much help in obtaining satisfactory results against bioﬁlm-associated infectious diseases.
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